1.18

15.96% -0.23

After Hours: 1.15 -0.03 -2.54%

Allarity Therapeutics Inc (ALLR)

Overview News Price History Financials Discussions Forecast Stock Split

Allarity Therapeutics Inc stock is traded at $1.18, with a volume of 2.31M. It is down -15.96% in the last 24 hours and up +5.80% over the past month. Allarity Therapeutics Inc is a clinical-stage, precision medicine company. The company is actively advancing a pipeline of in-licensed oncology therapeutics for patients with difficult-to-treat cancers. Its Drug Response Predictor (DRP) technology refines patient selection and improves clinical outcomes. Its pipeline product includes Dovitinib, Stenoparib, Ixempra, and other formulations.

Previous Close:

$1.41

Open:

$1.41

24h Volume:

2.31M

Relative Volume:

1.62

Market Cap:

$5.36M

Revenue:

Net Income/Loss:

$-11.90M

P/E Ratio:

-0.00573

EPS:

-206.0125

Net Cash Flow:

$-12.75M

1W Performance:

-10.23%

1M Performance:

+5.80%

6M Performance:

+571.01%

1Y Performance:

-85.72%

1-Day Range:

$1.12

$1.41

1-Week Range:

$1.12

$1.99

52-Week Range:

$0.1131

$9.60

Allarity Therapeutics Inc Stock (ALLR) Company Profile

Name

Allarity Therapeutics Inc

Sector

Healthcare (1179)

Industry

Biotechnology (675)

Phone

401-426-4664

Address

24 SCHOOL ST., 2ND FLOOR, BOSTON

Employee

Twitter

Next Earnings Date

Latest SEC Filings

ALLR's Discussions on Twitter

Compare ALLR with other stocks

Stocks	Price	Market Cap	Revenue	Net Income	Cash Flow	EPS
ALLR Allarity Therapeutics Inc	1.18	5.36M	0	-11.90M	-12.75M	-206.01
VRTX Vertex Pharmaceuticals Inc	438.40	113.67B	10.63B	-479.80M	-1.35B	-1.99
REGN Regeneron Pharmaceuticals Inc	683.08	74.97B	13.85B	4.65B	3.32B	40.41
ARGX Argen X Se Adr	665.68	40.50B	1.86B	-40.29M	-1.28B	-0.85
ALNY Alnylam Pharmaceuticals Inc	277.16	35.95B	2.09B	-332.26M	16.06M	-2.62
BNTX Biontech Se Adr	120.88	29.63B	3.30B	-501.07M	1.03B	-2.1146

Allarity Therapeutics Inc Stock (ALLR) Latest News

08:02 AM

Allarity Therapeutics Announces Filing of Form 8-K Regarding Settlement Agreement in Principle with SEC - GlobeNewswire

08:02 AM

08:00 AM

Allarity's Stenoparib Shows 14-Month Patient Response as Company Nears SEC Resolution - StockTitan

08:00 AM

Jan 29, 2025

2025-01-29 | Bronstein, Gewirtz & Grossman, LLC Is Investigating Allarity Therapeutics, Inc. (ALLR) And Encourages Investors to Connect | NDAQ:ALLR | Press Release - Stockhouse Publishing

Jan 29, 2025

Jan 26, 2025

2025-01-26 | Bronstein, Gewirtz & Grossman, LLC Encourages Allarity Therapeutics, Inc. (ALLR) Stockholders to Inquire about Securities Investigation | NDAQ:ALLR | Press Release - Stockhouse Publishing

Jan 26, 2025

Jan 20, 2025

No Stopping Allarity Therapeutics Inc (NASDAQ: ALLR)’s Stock Surged? - Stocks Register

Jan 20, 2025

Jan 19, 2025

2025-01-19 | Allarity Therapeutics, Inc. (ALLR) Investigation: Bronstein, Gewirtz & Grossman, LLC Encourages Shareholders to Contact the Firm to Learn More About the Investigation | NDAQ:ALLR | Press Release - Stockhouse Publishing

Jan 19, 2025

Jan 15, 2025

2025-01-15 | Bronstein, Gewirtz & Grossman, LLC Initiates an Investigation into Allegations Against Allarity Therapeutics, Inc. (ALLR) And Encourages Stockholders to Reach Out | NDAQ:ALLR | Press Release - Stockhouse Publishing

Jan 15, 2025

Jan 12, 2025

Bronstein, Gewirtz & Grossman, LLC Is Investigating Allarity Therapeutics, Inc. (ALLR) And Encourages Stockholders to Connect - AccessWire

Jan 12, 2025

Jan 09, 2025

SHAREHOLDER ALERT: Faruqi & Faruqi, LLP Investigates Claims on B - GuruFocus.com

Jan 09, 2025